» Articles » PMID: 30952767

Postoperative C-reactive Protein Is a Predictive Biomarker for Survival After Non-small Cell Lung Cancer Resection

Overview
Journal Anticancer Res
Specialty Oncology
Date 2019 Apr 7
PMID 30952767
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Preoperative C-reactive protein (CRP) is well recognized as a prognostic factor of non-small cell lung cancer (NSCLC). The present study aimed to elucidate the prognostic impact of postoperative CRP in patients with NSCLC following lung resection.

Patients And Methods: We retrospectively reviewed 336 patients with NSCLC treated with lung resection. CRP levels were measured at postoperative week 6 (CRP; range: 4-8 weeks). Patients were divided into two groups based on CRP median value (5.0 mg/l); the 5-year overall survival (OS) as well as the recurrence-free survival (RFS) was evaluated in both groups.

Results: Five-year OS and RFS were worse in the high-CRP group than in the low-CRP group (62.9% vs. 82.9%; p<0.001, 48.4% vs. 76.1%; p<0.001, respectively). Subgroup analysis for pathological stage I and ≥II also revealed worse OS in the high-CRP group. Multivariate analysis revealed an association between high CRP and worse OS (hazard ratio, 2.23; p<0.001).

Conclusion: CRP may serve as a prognostic biomarker in patients with resected NSCLC.

Citing Articles

Role of C-reactive protein in disease progression, diagnosis and management.

Ali S, Zehra A, Khalid M, Hassan M, Shah S Discoveries (Craiova). 2024; 11(4):e179.

PMID: 39554800 PMC: 11569793. DOI: 10.15190/d.2023.18.


Postoperative, but Not Preoperative, MELD-3.0 Prognosticates 3-Month Procedural Success in Patients Undergoing Orthotopic Heart Transplantation.

Ptak J, Sokolski M, Gontarczyk J, Mania R, Byszuk P, Krupka D J Clin Med. 2024; 13(19).

PMID: 39407876 PMC: 11477234. DOI: 10.3390/jcm13195816.


Perioperative Inflammatory Response and Cancer Recurrence in Lung Cancer Surgery: A Narrative Review.

Choi H, Hwang W Front Surg. 2022; 9:888630.

PMID: 35898583 PMC: 9309428. DOI: 10.3389/fsurg.2022.888630.


C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights.

Hart P, Rajab I, Alebraheem M, Potempa L Front Immunol. 2020; 11:595835.

PMID: 33324413 PMC: 7727277. DOI: 10.3389/fimmu.2020.595835.


Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis.

Milione M, Boeri M, Cantarutti A, Centonze G, Busico A, Suatoni P Cancers (Basel). 2020; 12(7).

PMID: 32646072 PMC: 7408913. DOI: 10.3390/cancers12071828.